During 2018–2022, more than 3,000 HTA decisions were made in the Europe top-5, and they steadily increased at an average annual growth rate (AAGR) of 27%.
In Lebanon, drug prices are reviewed and determined by the Ministry of Public Health (MoPH) during the registration process.
Historically, Japan performs scheduled biannual price adjustments as a cost-reduction method.
Branded medicines accounted for roughly 76% of Lebanon’s pharmaceutical market in 2022, according to GlobalData’s POLI database.
Risk-sharing agreements (RSAs) aim to mitigate the risks of including high-cost drugs on reimbursement lists and healthcare plans.
Give your business an edge with our leading industry insights.
A review of 17 medicines first available via the early access scheme found their price negotiation caused an average cut of 15.9%.